Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 5.2M | 243.5% |
| Gross Profit | 4.5M | 454.8% |
| Cost of Revenue | 700,000 | 0% |
| Operating expense | 20M | 9.1% |
| Net Income | -17M | 15.5% |
| EBITDA | -15M | 18.5% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 52M | 21.6% |
| Total Liabilities | 65M | 0.8% |
| Shares Outstanding | 42M | 0.1% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -16M | 18% |
| Cash from investing | -11,000 | 0% |
| Cash from financing | -640,000 | 3.2% |
EPS
Financial Highlights for Verrica Pharmaceuticals in Q2 '24
Verrica Pharmaceuticals reported a revenue of 5.2M, which is a 243.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 4.5M, marking a 454.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 700,000, a 0% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 20M, showing a -9.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a 15.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -15M, showing a 18.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Verrica Pharmaceuticals with growth in revenue, gross profit, and net income.
